5/17/2013

Rib-X Pharmaceuticals initiated a late-stage trial to assess the efficacy of a Captisol-enabled IV formulation of delafloxacin in patients with acute bacterial skin and skin structure infections. The trial triggered the payment of a $500,000 milestone fee to partner Ligand Pharmaceuticals.

Related Summaries